DCGI approves AstraZeneca 's Olaparib film-coated tablets
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Therapy recently approved in Canada under the brand name KORSUVA
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Collaboration supports multiple discovery efforts, including vaccines
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Subscribe To Our Newsletter & Stay Updated